Cellectis SA (CLLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.81 is considered Undervalued compared with the five-year average of -1.75. The fair price of Cellectis SA (CLLS) is between 4.06 to 7.24 according to relative valuation method. Compared to the current price of 3.80 USD , Cellectis SA By Undervalued By 6.49%.

Relative Value

Fair Zone

4.06-7.24

Current Price：3.80

6.49%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cellectis SA (CLLS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cellectis SA (CLLS) has a current Price-to-Book (P/B) ratio of 3.46. Compared to its 3-year average P/B ratio of 1.61, the current P/B ratio is approximately 114.75% higher. Relative to its 5-year average P/B ratio of 1.58, the current P/B ratio is about 119.03% higher. Cellectis SA (CLLS) has a Forward Free Cash Flow (FCF) yield of approximately -8.82%. Compared to its 3-year average FCF yield of -14.54%, the current FCF yield is approximately -39.33% lower. Relative to its 5-year average FCF yield of -31.73%, the current FCF yield is about -72.19% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CLLS competitors is 13.79, providing a benchmark for relative valuation. Cellectis SA Corp (CLLS.O) exhibits a P/S ratio of 4.81, which is -65.11% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CLLS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CLLS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CLLS currently overvalued or undervalued?

What is Cellectis SA (CLLS) fair value?

CLLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cellectis SA (CLLS) is between 4.06 to 7.24 according to relative valuation method.

How does CLLS's valuation metrics compare to the industry average?

The average P/S ratio for CLLS's competitors is 13.79, providing a benchmark for relative valuation. Cellectis SA Corp (CLLS) exhibits a P/S ratio of 4.81, which is -65.11% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Cellectis SA (CLLS) as of Mar 03 2026?

As of Mar 03 2026, Cellectis SA (CLLS) has a P/B ratio of 3.46. This indicates that the market values CLLS at 3.46 times its book value.

What is the current FCF Yield for Cellectis SA (CLLS) as of Mar 03 2026?

As of Mar 03 2026, Cellectis SA (CLLS) has a FCF Yield of -8.82%. This means that for every dollar of Cellectis SA's market capitalization, the company generates -8.82 cents in free cash flow.

What is the current Forward P/E ratio for Cellectis SA (CLLS) as of Mar 03 2026?

As of Mar 03 2026, Cellectis SA (CLLS) has a Forward P/E ratio of -4.69. This means the market is willing to pay $-4.69 for every dollar of Cellectis SA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cellectis SA (CLLS) as of Mar 03 2026?

As of Mar 03 2026, Cellectis SA (CLLS) has a Forward P/S ratio of 4.81. This means the market is valuing CLLS at $4.81 for every dollar of expected revenue over the next 12 months.

CLLS Valuation